Anaconda Biomed recently announced a $56 million funding round to advance what it describes as next-generation, novel thrombectomy catheters.
The Barcelona-based company said the funds will support completion of the ongoing Athena pivotal IDE study, a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter.
Omega Funds led the round, along with new investor Spain’s Co-investment fund (FOCO, which is managed by COFIDES). There was also continued participation from Asabys Sabadell Asabys II), Ysios Capital, and CDTI (through its SICC Innvierte).
Read full article: https://www.massdevice.com/anaconda-biomed-brings-in-56-million/
